濟川藥業(600566.SH):濟川有限簽署戰略合作框架協議 擬共同成立聯合創新藥投資基金
格隆匯9月18日丨濟川藥業(600566.SH)公佈,2020年9月18日,公司全資子公司濟川藥業集團有限公司(以下簡稱“濟川有限”)與博遠資本於上海簽訂《戰略合作框架協議》。經雙方友好協商,達成戰略合作事項。
雙方擬共同以設立合夥企業的方式投資成立聯合創新藥投資基金。博遠資本作為基金管理人,濟川有限作為有限合夥人,基金由專業基金管理團隊運營管理,雙方將共同負責基金管理團隊的搭建以及籌建工作。
聯合創新藥投資基金將以靈活的方式開展投資,包括針對有價值的產品進行控股併購型的投資以及針對技術型的早期目標進行孵化運營模式的投資以及傳統的股權投資模式等,基金將致力於包括但不限於以下行業領域的投資:
1、疾病領域:依託濟川有限的市場和營銷資源優勢,重點佈局兒科、呼吸系統、消化道、婦科領域藥物。除了重點領域之外,也將關注符合濟川發展戰略的重大疾病領域的醫療需求。
2、新藥物形態:例如基因治療藥物、核酸藥物、細胞藥物等;
3、下一代製藥技術:聚焦多種學科交叉和融合的新一代製藥技術(如DEL編碼庫技術、PROTAC技術、計算機輔助結構生物學分子設計、人工智能輔助靶標預測、分子設計、臨牀預測等)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.